

**CURRICULUM VITAE
MARC FISHER, MD**

OFFICE ADDRESS: U. Mass. Memorial Health Care
119 Belmont Street Phone: (508) 334-6641
Worcester, Massachusetts 01605 Telefax: (508) 334-6695
E-mail: FisherM@UMMHC.ORG

EDUCATION:

1966-1970 B.S. with distinction - Cornell University
1970-1974 M.D. - State University of New York at Syracuse - Alpha Omega Alpha

POSTGRADUATE TRAINING:

1974-1975 Intern (medicine) University of Wisconsin Hospitals
1975-1978 Neurology Residency - Medical Center Hospital of Vermont
1979 Board certification in Neurology

ACADEMIC APPOINTMENTS:

1978-1984 Assistant Professor of Neurology - University of Massachusetts Medical School
1984-1989 Associate Professor of Neurology - University of Massachusetts Medical School
1989- Professor of Neurology - University of Massachusetts Medical School
1991- Professor of Radiology - University of Massachusetts Medical School
1994- Affiliated Professor of Biomedical Engineering - Worcester Polytechnic Institute
1998 - Vice Chairman, Department of Neurology, University of Massachusetts Medical School

HOSPITAL APPOINTMENTS:

1978- University of Massachusetts Medical Center
1979- The Medical Center of Central Massachusetts - Memorial
St. Vincent Hospital, Worcester, Massachusetts (resigned)

SOCIETIES AND ORGANIZATIONS:

American Academy of Neurology - Fellow
American Heart Association - Stroke Council
Medical Advisory Board, Massachusetts Multiple Sclerosis Society, 1979-1988
Board of Trustees, Massachusetts Multiple Sclerosis Society, 1979-1988
American Neurological Association
World Stroke Organization-Board of Directors

ADMINISTRATIVE EXPERIENCE:

Coordinator, University of Massachusetts Neurology Residency, 1978-1983
Chief, Neurology Service, The Medical Center of Central Massachusetts - Memorial, 1983-1998

UNIVERSITY TEACHING ROLES:

Coordinator, Neurology resident education, University of Massachusetts Medical Center, Neurology Residency, 1978-1983
Coordinator, Neurology post-graduate education, University of Massachusetts Medical School, 1978-1983
Lecturer, Neuropathology courses, University of Massachusetts Medical School, 1979-present

EDITORIAL BOARD:

Cerebrovascular Diseases 1991-2002, 2006- *Journal of Stroke and Cerebrovascular Diseases*, *The Journal*

of the Neurological Sciences, European Neurology 1995-2000, *Stroke* (section editor, emerging therapies, associate editor 2007-), *Annals of Neurology* 2000-2006

EDITORIAL REVIEW:

Archives of Internal Medicine, Neurology, JAMA, NEJM, Archives of Neurology, Neuroepidemiology, Journal of Cerebral Blood Flow and Metabolism, Brain Research

NATIONAL AND INTERNATIONAL COMMITTEES:

1. Organizing committee, 2nd International Conference of the International Stroke Society, Washington, DC, 1992.
2. American Academy of Neurology, Annual Meeting sub-committee, 1993-1999.
3. Co-organizer IBC Conference on Acute Ischemic Stroke, Philadelphia, July 1993.
4. Local organizing committee, 19th Princeton Conference, Boston, MA, 1994.
5. Principal Organizer for STAIR conferences 1999, 2000, 2002
6. National Stroke Association Task Force on Legislative Lobbying, Chairman acute stroke treatment section 2000-2002
7. Board of Directors, National Stroke Association:2003-
8. Co-chairman, Princeton Conference, 2004
9. Section director for cerebrovascular disease, AAN annual meeting, 2002-2004
10. Program committee, ASA International Stroke Conference, 2004-2007
11. Board of Directors International Stroke Society/World Stroke Organization, 2003-2008
12. Executive committee, World Stroke Organization, member at large, 2008-

INVITED NATIONAL AND INTERNATIONAL SPEAKING ENGAGEMENTS:

- 1980 - Massachusetts Heart Association Stroke course, Boston: Stroke management
- 1983 - Dartmouth Medical School: Atherosclerosis: an overview
- 1984 - University of Vermont College of Medicine: Neurologic complications of heart disease
- 1984 - Participant, Consensus Conference on Antithrombotic Therapy sponsored by American College of Chest Physicians and NHLBI
- 1985 - Santa Clara County, California, Chapter American Heart Association: Atherosclerosis: a neurologist's perspective
- 1985 - Texas Tech Health Sciences Center: Neurologic complications of heart disease
- 1985 - Conference on Hemostasis and Thrombosis, Tufts University School of Medicine, Boston: Diagnosis and management of ischemic cerebral vascular disease.
- 1985 - Rutgers Medical School at Camden: Stroke diagnosis and management
- 1986 - Massachusetts General Hospital, Boston: Atherogenesis
- 1987 - Boston University School of Medicine: The pathogenesis and treatment of atherosclerosis
- 1987 - White Plains Medical Center: The pathogenesis and treatment of atherosclerosis
- 1987 - University of Southern California: Thrombolytic therapy in experimental stroke
- 1987 - Brown University-Roger Williams Hospital: Atherosclerosis, a neurologist's perspective.
- 1987 - Genesee Hospital-University of Rochester: Overview of atherosclerosis.
- 1988 - University of Dusseldorf, West Germany: Thrombolytic therapy for the neurologist.
- 1988 - Dartmouth Medical School: The potential health benefits of Omega-3 fatty acids
- 1988 - Toronto Stroke Conference: Fibrinolytic therapy and stroke.
- 1989 - 15th International Stroke Conference: Chair, Poster session
- 1989 - Henry Ford Hospital: Atherogenesis
- 1989 - 1st International Stroke Congress: Chair, Poster session on drug therapy of cerebral ischemia
- 1989 - American Heart Association, Plenary Session: Cerebral hemorrhagic complications of fibrinolytic therapy.
- 1990 - American Academy of Neurology: Course director for breakfast seminar: Carotid atherosclerosis.
- 1990 - New England Medical Center: Atherosclerosis overview.
- 1990 - International workshop: Cerebral-ischemia and dementia: cellular aspects of atherosclerosis, Prien-Chemsee, Germany.

- 1990 - University of Vermont Contemporary Neurology in Clinical Practice Course: TIA, reversible ischemia and stroke.
- 1990 - University of Istanbul: Stroke diagnosis and treatment.
- 1990 - IRIS Symposium on Acute Cerebral Ischemia: Clinical pharmacology of acute cerebral ischemia, Istanbul, Turkey.
- 1990 - University of Rome: Atherosclerosis: pathogenesis and treatment.
- 1991 - SUNY at Syracuse: Atherosclerosis: pathogenesis and treatment.
- 1991 - American Academy of Neurology: Course director for dinner seminar: Carotid atherosclerosis.
- 1991 - European College of Neuropsychopharmacology, Monte Carlo: Free radicals and cerebral ischemia.
- 1991 - University of Heidelberg: Diffusion weighted MRI and experimental stroke model.
- 1991 - University of Würzburg: Diffusion weighted MRI and experimental stroke model.
- 1992 - Lausanne-Geneva Neurology Meeting: New MRI technology for stroke diagnosis.
- 1992 - American Academy of Neurology: Course director for dinner seminar: Carotid atherosclerosis.
- 1992 - Boston University School of Medicine: New MRI techniques for stroke diagnosis.
- 1992 - Tufts-New England Medical Center: New MRI techniques for stroke diagnosis.
- 1993 - American Academy of Neurology: Course director for dinner seminar: New MRI technology for cerebrovascular disease.
- 1993 - 2nd International Conference on Stroke: Treatment of atherosclerosis. Geneva.
- 1993 - 7th Nordic Stroke Conference, Jyväskylä, Finland: New MRI technology for stroke diagnosis.
- 1993 - 2nd IBC Stroke Conference, Philadelphia: New MRI Technology.
- 1993 - West China University of Medical Sciences, Chengdu, Sichuan, China: Visiting Professor.
- 1994 - Massachusetts General Hospital: Evolving towards stroke therapy.
- 1994 - 19th Princeton Conference, Boston: Overview of neuroprotective stroke therapy.
- 1994 - 3rd International Thrombolytic Therapy Conference, Nara, Japan: New MRI Technology for evaluating stroke.
- 1994 - American Academy of Neurology, Course director for dinner seminar: New MRI technology for cerebrovascular disease.
- 1994 - 3rd European Stroke Society Meeting, Stockholm, Invited Lecture: Prophylactic neuroprotection.
- 1994 - Aring-Merritt Symposium, Cincinnati: New MRI technology for stroke.
- 1994 - Cleveland Clinic: New MRI technology for stroke.
- 1994 - Rush-Presbyterian Medical Center, Chicago: Stroke therapy.
- 1995 - Danish Neurological Society, Copenhagen, Denmark: New MRI technology for stroke.
- 1995 - American Academy of Neurology, Course director for dinner seminar: New MRI techniques for cerebrovascular disease.
- 1995 - European Stroke Society Satellite Symposium, Bordeaux, France: Leukocytes and cerebral ischemia.
- 1995 - Chinese Stroke Society, Chengdu, Sichuan, PRC: Advances in acute stroke therapy.
- 1995 - Beijing Hospital, Beijing, PRC: Acute stroke therapy.
- 1996 - 3rd World Stroke Congress, Munich: Neuroprotective Therapy.
- 1996 - 4th Thrombolytic Therapy Conference, Copenhagen, Multi-therapy for Stroke.
- 1996 - Stroke Symposium, Heidelberg, Germany: Diffusion-Perfusion MRI.
- 1996 - American Academy of Neurology, course director for dinner seminars: New MRI Techniques for Cerebrovascular Disease.
- 1997 - American Academy of Neurology: Cerebrovascular disease course; imaging of acute stroke.
- 1997 - American Society of Neuroradiology Annual Meeting: The Pathophysiology of Ischemic Stroke.
- 1997 - Lausanne Switzerland, Stroke Symposium: Neuroprotective therapy.
- 1997 - University of Antalya, Turkey: Acute Stroke Therapy.
- 1997 - Australo-Asian Stroke Society: Acute Stroke Therapy.
- 1998 - Course Director, Stroke Therapy, American Academy of Neurology Annual Meeting.
- 1998 - University of Istanbul, Update on Stroke Therapy.
- 1998 - MIT Stroke Symposium, Neuroprotective Therapy.
- 1998 - Boehringer Ingelheim Stroke Symposium, Crete: MRI Application for Acute Ischemic Stroke.
- 1998 - Neurology Grand Rounds, Massachusetts General Hospital: Acute Stroke Therapy
- 1999 - Course Director, Cerebrovascular Disease: American Academy of Neurology Annual Meeting.

- 1999 - Organizer: Stroke Therapy Academic Industry Round Table - 1, Orlando, FL
- 1999 - 8th European Stroke Society Meeting, Venice, Pharmacological Approaches to Recovery After Stroke.
- 1999 - Summer Pathology Course - University of Helsinki, Applying diffusion-perfusion MRI to stroke drug development.
- 1999 - Organizer, Stroke Therapy Symposium, Whittier Rehabilitation Hospital, Westboro, MA
- 1999 - Neurology Grand Rounds, Yale University: Acute Stroke Therapy.
- 2000 - Neurology Grand Rounds, Brown University: Acute Stroke Therapy.
- 2000 - Organizer: Stroke Therapy Academic Industry Round Table - 2, Palo Alto, CA.
- 2000 - Course Director, Cerebrovascular Disease: American Academy of Neurology Annual Meeting.
- 2000 - 9th European Stroke Society Meeting, Vienna: Imaging of Acute Stroke.
- 2000 - Stroke Symposium: Moscow State University: Imaging of Acute Stroke, Acute Stroke Therapy.
- 2000 - 5th Annual symposium on applied physiology of the peripheral circulation, Pittsburg, PA, Diffusion-Perfusion MRI.
- 2000 - Neurology Grand Rounds, Boston University: Acute Stroke Therapy.
- 2000 - Organizer: Stroke Update, Whittier Rehab, Westboro, MA.
- 2000 - Boehringer-Ingelheim Stroke Symposium, Bermuda, Neuroprotection Future Prospects.
- 2000 - 4th International Stroke Society Meeting, Melbourne, Current status of neuroprotective therapy, Bristol-Myers Symposium
- 2000 - 4th International Stroke Society Meeting, Melbourne, Using diffusion-perfusion MRI in animal stroke models
- 2000 - 6th Thrombolytic Therapy Meeting, Hamilton Island Australia, Animal modeling and diffusion-perfusion MRI
- 2001 - American Stroke Society Annual Meeting: Diffusion Perfusion MRI Applications in Experimental Stroke, Ft. Lauderdale
- 2001 - Japanese Stroke Society Meeting, Overview of Acute Stroke Therapy, Osaka
- 2001 - Mediterranean Stroke Society, The Ischemic Penumbra, Istanbul
- 2001 - Mediterranean Stroke Society, Current Status of Neuroprotection, Istanbul
- 2001 - Chinese Cerebrovascular Society, Thrombolytic Therapy: Current Status and Future Directions, Guangzhou
- 2001 - Chinese Stroke Society, Current Status of Neuroprotection, Guangzhou
- 2001 - Course Director, Cerebrovascular Disease, American Academy of Neurology Annual Meeting, Philadelphia
- 2001 - National Stroke Association Annual Meeting, Neuroprotective therapy for stroke, San Diego
- 2002 - American Stroke Association Annual Meeting, What imaging tools should be used to evaluate carotid stenosis? San Antonio
- 2002 - University of Helsinki, Using diffusion/perfusion MRI for stroke drug development.
- 2002 - Course Director, Cerebrovascular Disease, American Academy of Neurology Annual Meeting, Denver
- 2002 - Stroke Symposium - The Ischemic Penumbra. Madrid Spain
- 2002 - Stroke Rounds, University of Miami - Stroke Prevention
- 2002 - Neurology Grand Rounds, Beth Israel Hospital - Current Status of Acute Stroke Therapy
- 2002 - German Neurological Society - The STAIR meetings, Mannheim, Germany
- 2002 - National Stroke Association Annual Meeting - Developing Acute Stroke Therapy, Orlando, FLA
- 2003 - Boehringer-Ingelheim Stroke Speakers Meeting - Cardiologists approach to stroke prevention, Naples FLA
- 2003 - American Stroke Association Annual Meeting - Symposium Director, Bridging the gap between basic science and development of acute stroke therapies, Phoenix, AZ
- 2003 - Mediterranean Stroke Society, Current Status of Neuroprotection, Nice
- 2003 - First Russian International Cerebrovascular Disorders Congress, Developing neuroprotective therapy, Moscow
- 2003 - Course Director and speaker, Whittier Annual Neurology Symposium, stroke prevention, Westboro, MA
- 2003 - Neurology Grand Rounds, Cornell University School of Medicine, Developing new acute stroke treatments, New York

2003 National Stroke Association Annual Meeting, Developing Acute Stroke Therapy, Orlando
 2004 Fourth STAIR meeting, organizer, Baltimore
 2004 World Stroke Congress Symposium Director, Improving Acute Stroke Trials, Vancouver
 2004 Cleveland Clinic Symposium on Neurocritical Care, The future of acute stroke therapy, Cleveland
 2005 Asian-Pacific Stroke Conference-Developing Future Acute Stroke Therapies, Chiang Mai, Thailand
 2005 Asian-Pacific Stroke Conference- Neuroprotection, dream or reality, Chiang Mai, Thailand
 2005 American Stroke Association, International Stroke Conference, Regulatory approval for stroke therapies, New Orleans
 2005 Swiss Neurological Society, Thrombolysis beyond 3 hours: yes or no, Berne Switzerland
 2005 European Stroke Conference, Pleotropic effects of statins, Bologna Italy
 2005 European Stroke Conference, Neuroprotection and the ischemic penumbra, Bologna, Italy
 2005 Grand Rounds, University of Reykjavic, Iceland, Developing acute stroke therapy.
 2005 Grand Rounds, Medical University of South Carolina, Current and future acute stroke therapy
 2005 National Stroke Association Health Care Summit, Stroke Risk Factors, Denver
 2006 Stroke Symposium, University of Massachusetts Medical School, Acute Stroke Therapy
 2006 American Stroke Association, International stroke conference, Orlando, Future Implications of the SAINT-I trial
 2006 European Neurological Society Meeting, Lausanne Switzerland, Current and future acute stroke therapy.
 2006 National Stroke Association, Regional meeting, Boston, Update on treating acute ischemic stroke
 2006 Tel Aviv University Medical School, Developing and implementing acute stroke therapy.
 2006 NSA regional meeting, Boston MA Overview of acute stroke therapy
 2006 Fifth International Stroke Society Meeting, Capetown South Africa, Animals models and acute stroke therapy development
 2006 Neurology Grand Rounds, University of Western Ontario, Translational medicine and acute stroke therapy development
 2007 American Stroke Association, International Stroke Conference, San Francisco, Neuroprotection after the failure of SAINT-II.
 2007 Neurology Grand Rounds, Buffalo General Hospital, Stroke prevention
 2007 59th American Academy of Neurology Annual Meeting, Boston, course director, Stroke Therapy evening symposium, lecture, stroke prevention.
 2007 European Stroke Conference, Laser Light therapy to enhance stroke recovery, Glasgow, Scotland
 2007 Australian Translational Stroke Symposium. Approaches to translational stroke research. Melbourne Australia
 2007 Neurology Grand Rounds, Univ of Texas, Houston, Translational stroke research, Houston, Texas
 2008 Neurology Grand Rounds, Yonsei University College of Medicine, Seoul, Korea, Developing Acute Stroke Therapy
 2008 Medicine Grand Rounds, National University Hospital of Singapore, Singapore, Past, Present and Future Acute Stroke Therapy
 2008 American Stroke Association, International stroke Conference, New Orleans, Clinical development of normobaric hyperoxia.
 2008 Neurology Grand Rounds, Downstate Medical Center, Brooklyn NY, Developing acute stroke therapy
 2008 European Stroke Conference, Enhancing thrombolytic therapy availability with telemedicine, Nice France
 2008 Thrombolysis and Neuroprotection Update, Budapest Hungary, What is in the pipeline for neuroprotection.
 2008 Sixth World Stroke Organization Meeting, Vienna Austria, Teaching course on clinical trials-designing acute stroke trials and regulatory considerations for acute stroke trials
 2008 Spanish Neurology Society Meeting, Barcelona, Developing extended time window stroke therapies.
 2009 American Stroke Association, International Stroke Conference, San Diego, Late time window acute stroke therapy development.
 2009 Stroke Symposium, Chengdu, China, Developing acute stroke therapy in an extended time window
 2009 Stroke Symposium, Chengdu, China, Translational approaches to stroke research

2009 Biopolis, Singapore, Applying translational research approaches to developing novel stroke therapies
 2009 19th European Stroke Conference, Stockholm, Applications of high flow oxygen for acute ischemic stroke
 2009 23rd Nordic Stroke Conference, Helsinki, What is in the pipeline for acute stroke therapies
 2009 23rd Nordic Stroke Conference, Helsinki, The ischemic penumbra and the development of acute stroke therapy

PUBLICATIONS:

1. Fisher M, Poser CM. Syphilitic Meningomyelitis. *Arch Neurol* 1977; 34:785.
2. Roman G, Fisher M, Perl D, Poser CM. Neurologic Manifestations of Hereditary Hemorrhagic Telangiectasia. *Ann Neurol* 1978; 4:130-144.
3. Fisher M. Holter Monitoring Inpatients with Transient Focal Cerebral Ischemia. *Stroke* 1978; 9: 514-516.
4. Fisher M, Sargent J, Drachman DA. Familial Inverted Choreoathetosis. *Neurology* 1979; 29: 1627-1631.
5. Fisher M, Davidson RI, Marcus EM. Transient Focal Cerebral Ischemia as a Presenting Manifestation of Unruptured Cerebral Aneurysms. *Ann Neurol* 1980; 8:367-372.
6. Fisher M, Levine PH, Fullerton AL, Duffy CP, Hoogasian JJ. Excessive Factor VIII Coagulant Activity in Transient Ischemic Attacks. *Trans Amer Neur Assoc* 1980; 105:74-76.
7. Fisher M, McQuillen JB. Bilateral Cortical Border-zone Infarction. *Arch Neurol* 1981; 38:62-63.
8. Levine PH, Fisher M, Fullerton AL, Duffy CP, Hoogasian JJ. Human Platelet Factor IV; Preparation From Out-dated Platelet Concentrates, and Application in Cerebral Vascular Disease. *AM J Hematology* 1981; 10:375-385.
9. Sebastian PR, Fisher M, Smith TW, Davidson RI. Intramedullary Spinal Cord Metastasis. *Surg Neur* 1981; 16:336-339.
10. Fisher M, Long RR, Drachman DA. Amyotrophy in Multiple Sclerosis: A Pseudogenic Process. *Trans Amer Neurol Assoc.* 1981; 106:263-265.
11. Fisher M, Levine PH, Fullerton AL, Forsberg A, Duffy CP, Hoogasian JJ, Drachman DA. Marker Proteins of Platelet Activation in Patients with Cerebrovascular Disease. *Arch Neurol* 1982; 30:492-495.
12. Fisher M, Weiner B, Ockene IS, Forsberg A, Duffy CP, Levine PH. Platelet Activation and Mitral Valve Prolapse. *Neurology* 1983; 33:384-386.
13. Fisher M, Zito JL. Focal Cerebral Ischemia Distal To a Cerebral Aneurysm in Hereditary Hemorrhagic Telangiectasia. *Stroke* 1983; 14:419-421.
14. Fisher M, Long RR, Drachman DA. Hand Muscle Atrophy in Multiple Sclerosis. *Arch Neurol* 1983; 40:811-815.
15. Fisher M, Budnitz E. Focal Cerebral Ischemia and Mitral Valve Prolapse. *Arch Int Med* 1983; 143: 2180-2181.
16. Fisher M, Weiner B, Ockene IS, Hoogasian JJ, Natale AM, Arsenault JR, Johnson MH, Levine PH. Selective Thromboxane Inhibition: A New Approach to Antiplatelet Therapy. *Stroke* 1984; 15:813-16.
17. The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia: endpoint results. *Stroke* 1985; 16:406-15.
18. Russell J, Fisher M, Sullivan J, Zivin JA, Drachman DA. EB Virus Encephalopathy Presenting as Status Epilepticus. *Arch Neuro* 1985; 42:789-93.
19. Fisher M, Maister B, Jacobs R. Hypertensive Encephalopathy: Diffuse Reversible White Matter CT Abnormalities. *Ann Neurol* 1985; 18:268-70.

PUBLICATIONS: (continued)

20. Zivin J, Fisher M, DeGirolami V, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. *Science* 1985; 230:1289-92.
21. Dyken ML, Fisher M, Harrison MJG, Hart RG, Sherman DG. (Cerebral embolism task force). Management of cerebral embolism. *Arch Neurol* 1986; 43:71-84.
22. The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemic - Part III: Risk Factors in Stroke. 1986; 17:12-18.
23. Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Cerebral embolism. *Chest* 1986; 89:82S-98S.
24. Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Cerebral Embolism. *Arch Int Med* 1986;146:471-2.
25. Przelomski MM, Fisher M, Davidson RI, Jones HR, Marcus EM. Unruptured intracranial aneurysm and transient focal cerebral ischemia - A followup study. *Neurology* 1986;36:584-87.
26. Fisher M, Levine PH, Weiner B, et al. The effect of vegetarian diets on plasma lipids and platelets. *Arch Int Med* 1986;146:1193-1197.
27. Fisher M, Upchurch KS, Levine PH, et al. Effects of dietary fish oil supplementation on polymorphonuclear inflammatory potential. *Inflammation* 1986;10:387-92.
28. Fisher M, Levine PH, Weiner BH. The potential clinical benefits of fish consumption. *Arch Int Med* 1986;146:2322-2323.
29. Weiner BH, Ockene IS, Levine PH, Cuenod H, Fisher M, et al. Inhibition of atherosclerosis by cod liver oil in a hyperlipidemic swine model. *N Engl J Med* 1986;315:841-46.
30. Cerebral Embolism Study Group. Cardioembolic Stroke, Early Anti-Coagulation, and Brain Hemorrhage. *Arch Int Med* 1987;147:636-640.
31. Wyrzles L, Markley HFG, Fisher M, Alfred H. Multiple Mononeuropathies Complicating Brachial Artery-antecubital Vein Shunting. *Neurology* 1987; 37:1398-1400.
32. Fisher M, Johnson MH, Natale AM, Levine PH. Linoleic Acid Levels in White Blood Cells, Platelets and Serum of Multiple Sclerosis Patients. *Acta Neurol Scand* 1987;76:241-245.
33. Fisher M, Blumenfeld A, Smith TW. The importance of carotid artery plaque disruption and hemorrhage. *Arch Neurol* 1987;44:1086-1089.
34. Fisher M, Levine PH, Weiner BH. Atherosclerosis and the benefits of omega-3 fatty acids. *Laboratory Management* 1987; 25:26-31.
35. Fisher M, Smith TW, Jacobs R. Pure motor hemiplegia secondary to a saccular basilar artery aneurysm. *Stroke* 1988; 19:104-107.
36. Fisher M, Levine PH, Weiner BH, Vaudreuil CH, Natale AM, Grammel TM, Johnson MH, Hoogasian JJ. Monocyte and polymorphonuclear leukocyte toxic oxygen metabolism production in MS. *Inflammation* 1988; 12:123-131.
37. Phillips DA, Fisher M, Smith TW, Davis M. Safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. *Ann Neurol* 1988; 23:391-394.
38. Fisher M, Kase CS, Stelle B, Mills RM. Ischemic stroke after cardiac pacemaker implantation in sick sinus syndrome. *Stroke* 1988; 19:712-715.
39. Phillips DA, Davis M, Fisher M. Selective embolization and clot dissolution in the internal carotid artery circulation of the rabbit: An improved stroke model. *AJNR* 1988;9:899-902.
40. Fisher M, Recht L. Brain tumor presenting as an acute pure motor hemiparesis: Report of three cases. *Stroke* 1989; 20:288-291.
41. Phillips DA, Fisher M, Smith TW, Davis MA, Pang RHL. The effects of a new t-PA analogue, Fb-Fb-CF on cerebral reperfusion in a rabbit embolic stroke model. *Ann Neurol* 1989; 25:281-285.
42. Goodnight S, Fisher M, Fitzgerald GA, Levine PH. An assessment of the therapeutic use of

- dietary fish oil in atherosclerotic vascular disease. *Chest* 1989;95:19S-25S.
43. Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Antithrombotic therapy and cerebral embolism. *Chest* 1989;95:140S-155S.
 44. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. *Arch Neurol* 1989;46:676-680.
 45. Levine PH, Fisher M, Schneider PB et al. Dietary supplementation with omega-3 fatty acids prolongs platelet survival in hyperlipidemic patients with atherosclerosis. *Arch Int Med* 1989; 149:1113-1116.
 46. Yatsu FM, Fisher M. Atherosclerosis: Current concepts of pathogenesis and treatment. *Ann Neurol* 1989;26:3-12.
 47. Young SN, Fisher M, Sigsbee A, Errichetti A. Cardiogenic brain embolism and lupus anticoagulant. *Ann Neuro* 1989;26:390-392.
 48. Asinger M, Dyken ML, Fisher M, Harrison MJG, Hart RM, Sherman DG. Cardiogenic brain embolism. *Arch Neurol* 1989;46:727-743.
 49. Fisher M, Leaf A, Levine PH. N-3 fatty acids and cellular aspects of atherosclerosis. *Arch Int Med* 1989;149:1726-1728.
 50. Fisher M, Levine PH, Weiner BH, et al. Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte enriched preparation. *Am J Clin Nutr* 1990;51:804-808.
 51. Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia JI. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. *Ann Int Med* 1990;112:17-21.
 52. Philips DA, Fisher M, Smith TW, Davis MA, Pang RHL. Delayed treatment with a t-PA analogue and streptokinase in a rabbit embolic stroke model. *Stroke* 1990;21:602-605.
 53. Fisher M. Cerebral ischemia: drug therapy. *Stroke* 1990;21(Suppl D):130-131.
 54. Fisher M, Levine PH, Cohen RA. A 21-aminosteroid, U74500A, reduces hydrogen peroxide and chemiluminescence by stimulated human leukocytes. *Stroke* 1990;21:1435-1438.
 55. Fisher M, Levine PH, Doyle EM, Arpano MM, Bergeron DA, Cohen RA, Hoogasian JJ. A 21-aminosteroid inhibits stimulated monocyte hydrogen peroxide and chemiluminescence measurements from MS patients and controls. *Neurology* 1991;41:297-299.
 56. Hosley MA, Fisher M, Lingley JF. Thrombosis in a congenitally bifurcated superior sagittal sinus. *Stroke* 1991;22:396-400.
 57. Fisher M. Ischemic cerebral vascular disease. *Arz-Psiquiat (Sao Paulo)* 1991;49:1-10.
 58. Fisher M. Atherosclerosis: Cellular aspects and potential interventions. *Cerebrovascular and Brain Metabolism Reviews* 1991; 2:117-133.
 59. Fisher M. Clinical pharmacology of cerebral ischemia: old controversies and new approaches. *Cerebrovascular Diseases* 1991; 1(Suppl 1):112-119.
 60. Fisher M, Levine PH, Doyle EM, Arpano MM, Hoogasian JJ. A 21-aminosteroid inhibits oxidation of human LDL-cholesterol by human monocytes. *Atherosclerosis* 1991; 90:197-202.
 61. Fisher M. Free radicals and cerebral ischemia. *European Journal of Neuropsychopharmacology* 1991; 1:246-247.
 62. Minematsu K, Li L, Fisher M, Sotak CH, Davis MA. Diffusion weighted magnetic resonance imaging rapidly detects focal brain ischemic changes induced by suture occlusion of the rat middle cerebral artery. *Neurology* 1992; 42:235-240.
 63. Fisher M, Arpano MM. Inhibition of stimulated leukocyte hydrogen peroxide generation by a novel antioxidant. *J Neurol Sci* 1992; 109:107-111
 64. Minematsu K, Li L, Sotak CH, Davis MA, Fisher M. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging. *Stroke* 1992; 23:1304-1310.

65. Fisher M, Sotak CH, Minematsu K, Li L. Innovative magnetic resonance technologies for evaluating cerebrovascular disease. *Ann Neurol* 1992; 32:115-122.
66. Fisher M, Sotak CH. Diffusion-weighted MR imaging and ischemic stroke. *AJNR* 1992; 13:1103-1105.
67. Goodnight SH, Cairns JA, Fisher M, Fitzgerald GA. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. *Chest* 1992; 102:374S-384S.
68. Sherman DG, Dyken ML, Fisher M, Gent M, Harrison M, Hart RG. Antithrombotic therapy for cerebrovascular disorders. *Chest* 1992; 102:529S-537S.
69. Nunnari JJ, Fisher M, White SDT. Inhibition of lipid deposition in the hypercholesterolemic rat by clentiazem. *Exp Mol Pathol* 1992; 57:193-204.
70. Fisher M, Minematsu K. Lacunar stroke: diagnosis, evaluation and management. *Heart Disease and Stroke* 1992; 6:353-356.
71. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RN, Sotak CH. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. *Neurology* 1993; 42:397-403.
72. Cohen RA, Kessler HR, Fisher M. The extended disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. *J Neurol Sci* 1993; 115:132-135.
73. Minematsu K, Fisher M. MK-801 reduces extensive infarction after suture middle cerebral artery occlusion in rats. *Cerebrovasc Dis* 1993; 3:99-104.
74. Roman GC, Tatemich TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. *Neurology* 1993; 43:250-260.
75. Weiner HL, Mackin GA, Drau EJ, et al. Intermittent pulse therapy in progressive multiple sclerosis. *Neurology* 1993; 43:910-918.
76. Rizzo MA, Fisher M, Lock JP. Hypermagnesemic pseudocoma. *Arch Int Med* 1993; 153:1130-1132.
77. Fisher M, Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. *JAMA* 1993; 270:360-364.
78. Dardzinski BJ, Sotak CH, Fisher M, et al. Apparent diffusion coefficient mapping of experimental focal cerebral ischemia using echo planar diffusion weighted imaging. *Mag Res Med* 1993; 17:318-325.
79. Fisher M, Plante GM, Doyle EM. Inhibition of inflammatory cell-mediated myelin oxidation and interleukin 1-B generation by a 21-aminosteroid, U74500A. *J Neurol Sci* 1993; 119:189-194.
80. Minematsu K, Fisher M, Li L, Sotak CH. Diffusion and perfusion MRI studies to evaluate a non-competitive NMDA antagonist and reperfusion in experimental stroke. *Stroke* 1993; 24:2074-2081.
81. Meadows ME, Fisher M, Minematsu K. Delayed treatment with a non-competitive NMDA antagonist, CNS-1102, reduces infarct size in rats. *Cerebrovasc Dis* 1994; 4:26-31.
82. Hasegawa Y, Latour LL, Sotak CH, Dardzinski BJ, Fisher M. Temperature dependent changes of the apparent diffusion coefficient of water in normal and ischemic brain in rats. *J Cereb Blood Flow Metab* 1994; 14:383-390.
83. Fisher M, Jonas S, Sacco R. Prophylactic neuroprotection for cerebral ischemia. *Stroke* 1994; 25:1075-1080.
84. Hasegawa Y, Fisher M, Baron BM, Metcalf G. The competitive NMDA antagonist MDL-100,453 reduces infarct size after experimental stroke. *Stroke* 1994; 25:1241-1246.
85. Fisher M, Bogousslavsky J. A glimmer of hope for acute ischemic stroke. *Cerebrovasc Dis* 1994; 4:177-178.

86. Weaver JP, Fisher M. Subarachnoid hemorrhage: an update of pathogenesis, diagnosis and management. *J Neurol Sci* 1994; 125:119-131.
87. Hasegawa Y, Fisher M, Latour LL, Dardzinski BJ, Sotak CH. MRI diffusion mapping of reversible and irreversible ischemic injury in focal brain ischemia. *Neurology* 1994; 44:1484-1490.
88. Latour LL, Hasegawa Y, Formato JE, Fisher M. Spreading waves of decreased diffusion coefficient after cortical stimulation in a rat. *Mag Res Med* 1994; 34:189-198.
89. Reith W, Fisher M. Diffusion-weighted magnetic resonance mapping for acute ischemic stroke. *Vasc Med Rev* 1994; 5:307-310.
90. Cohen RA, Hasegawa Y, Fisher M. Effects of a novel NMDA antagonist on experimental stroke quantitatively assessed by spectral EEG and infarct volume. *Neurol Res* 1994; 16:443-448.
91. Reith W, Hasegawa Y, Latour LL, Dardzinski BJ, Sotak CH, Fisher M. Multislice diffusion mapping for 3-D evolution of cerebral ischemia in a rat stroke model. *Neurology* 1995; 45:172-177.
92. Fisher M. Potentially effective therapies for acute ischemic stroke. *Eur Neurol* 1995; 35:3-7.
93. Hasegawa Y, Latour L, Formato JE, Sotak CH, Fisher M. Spreading waves of a reduced diffusion coefficient of water in normal and ischemic rat brain. *J Cereb Blood Flow Metab* 1995; 15:179-187.
94. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. *JAMA* 1995; 11:908-911.
95. Adams RJ, Fisher M, Furlan AJ, del Zoppo G. Acute stroke treatment trials in the United States: Rethinking strategies for success. *Stroke* 1995; 12:2216-18. *Cerebrovasc Dis* 1995; 5:362-365.
96. Liu M, Fisher M, Yuan G, Hongbo Z. Early presentation of acute stroke in a Chinese population.
97. Fisher M, Meadows ME, Do T, Charette M, Finkelstein SP. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 1995; 15:953-59.
98. Fisher M. Diffusion and perfusion imaging for acute stroke. *Surg Neurol* 1995; 43:606-609.
99. Fisher M, Pessin MS, Furlan AJ (editorial). ECASS: Lessons for future stroke trials. *JAMA* 1995; 274:1058-59.
100. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. *JAMA* 1995; 274:908-911.
101. Silver B, Weber J, Fisher M. Medical therapy for ischemic stroke. *Clinical Neuropharmacology* 1996; 19:101-128.
102. Takano K, Latour LL, Formato JE, Carano RAO, Helmer KG, Hasegawa Y, Fisher M. The role of spreading depression in focal ischemia evaluated by diffusion mapping. *Ann Neurol* 1996; 39:308-318.
103. Schäbitz WR, Weber J, Takano K, Sandage BN, Locke KW, Fisher M. Effects of citicholine on infarct volume, mortality and behavioral outcome. *J Neurol Sci* 1996; 138:21-25.
104. Anwer UE, Fisher M. Acute and atypical presentations of syringomyelia. *Eur Neurol* 1996;36:215-218.
105. Fisher M, Garcia J. Evolving stroke and the ischemic penumbra. *Neurology* 1996;884-888.
106. Hasegawa Y, Foirmato JE, Latour LL, et al. Severe transient hypoglycemia causes reversible change in the apparent diffusion coefficient of water. *Stroke* 1996, 27:1648-1656.
107. Tatlisumak T, Fisher M. Hematologic disorders associated with ischemic stroke. *J Neurol Sci* 1996; 140:1-11.
108. Onal MZ, Fisher M. Thrombolytic and neuroprotective therapies for acute ischemic stroke.

- Drugs of Today 1996;32:573-592.
109. Li F, Fisher M. Diffusion-weighted and perfusion magnetic resonance imaging and ischemic stroke. *Drugs of Today* 1996;32:615-627.
 110. Tatlisumak T, Takano K, Carano RAD, Fisher M. Effect of basic fibroblast growth factor on experimental focal ischemia studied by diffusion-weighted and perfusion imaging. *Stroke* 1996;27:2292-2298.
 111. Reith W, Dardziński BJ, Sotak CH, Fisher M. Monitoring tissue plasminogen activates treatment with multislice diffusion mapping and perfusion imaging in a thromboembolic model. *Int J Neuroradiol* 1996;2:397-407.
 112. Fisher M. Characterizing the target of acute stroke treatment *Stroke* 1997;28:866-872.
 113. Onal MZ, Li F, Tatlisumak T, Locke KW, Sandage BW, Fisher M. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia. *Stroke* 1997;28:1060-1065.
 114. Takano K, Tatlisumak T, Formato J, et al. A Glycine Site Antagonist Attenuates Infarct Size in Experimental Focal Ischemia: Postmortem and Diffusion Mapping Studies. *Stroke* 1997;28:1255-1263.
 115. Li F, Irie K, Anwer U, Fisher M. Delayed triphenyltetrazolium chloride staining remains useful for evaluating cerebral infarct volume in a rat stroke model. *J Cereb Blood Flow Metab* 1997;12:1132-1135.
 116. Onal MZ, Fisher M. Acute ischemic stroke therapy. *Eur Neurol* 1997;38(3):141-159.
 117. Feuerstein GZ, Fisher M, Nunnari J, Ruffolo RR. Carvedilol inhibitor arotic lipid deposition in the hypercholesterolemic rat. *Pharmacology* 1997;54(1):24-32.
 118. Takano K, Tatlisumak T, Bergmann A, Gibson D, Fisher M. Reproducibility and reliability of middle cerebral artery occlusion using a silicone-coated suture (Koizumi) in rats. *J Neurol Sci* 1997;153:8-11.
 119. Takano K, Carano RAD, Tatlisumak T, et al. The efficacy of intraarterial and intravenous Prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging. *Neurology* 1998;50:870-875.
 120. Fisher M, Bogousslavsky J. Further evolution for effective therapy for acute ischemic stroke. *JAMA* 1998;279:1298-1303.
 121. Tatlisumak T, Takano K, Meiler MR, Fisher M. Glycine site antagonism reduces number of spreading depressions and infarct size in rats. *Stroke* 1998;29:190-195.
 122. Tatlisumak T, Carano RAD, Takano K, Opgenorth TJ, Sotak CH, Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion. *Stroke* 1998;29:850-858.
 123. Fisher M: The travails of neuroprotective drug development for acute ischemic stroke. *Eur Neurol* 1998;90:65-66.
 124. Li F, Han S, Tatlisumak T, Carano RAD, Irie K, Sotak CH, Fisher M. A new method to improve in-bore middle cerebral artery occlusion in rats: Demonstration with diffusion - and perfusion - weighted imaging. *Stroke* 1998;29:1715-1720.
 125. Tatlisumak T, Takano K, Carano RAD, Fisher M. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. *Stroke* 1998;29:1952-1959.
 126. Carano RAD, Takano K, Helmer KG, et al. Determination of focal ischemic lesion volume in the rat brain using multispectral analysis. *JMRI* 1998;8:1266-1278.
 127. Fisher M: Antithrombotic and thrombolytic therapy for ischemic stroke. *J Thrombosis and Thrombolysis* 1999;7:165-170.
 128. Schabitz W, Li F, Irie K, Sandage BW, Locke KW, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary focal ischemia. *Stroke* 1999;30:427-431.

129. Fisher M, Albers GW: Application of diffusion-perfusion magnetic resonance imaging in acute ischemic stroke. *Neurology* 1999;52:1750-1756.
130. Fisher M. Neuroprotection for acute ischemic stroke: Where are we? *The Neuroscientist* 1999;6:392- 401.
131. Li F, Carano RAD, Irie K, et al. Neuroprotective effects of a novel broad spectrum cation channel blocker LOE 908M5 on experimental focal ischemia. *JMRI* 1999; 10:138-145.
132. Li F, Haw S, Tatlisumak T, et al. Reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia in rats. *Ann Neurol* 1999;46:333- 342.
133. Fisher M, Finklestein SP. Pharmacological approaches to stroke recovery. *Cerebrovasc Dis* 1999;9(suppl):29-32.
134. Li F, Omae T, Fisher M. Spontaneous hyperthermia and its mechanism in the intraluminal suture middle cerebral artery occlusion model of rats. *Stroke* 1999;30:2464-2470.
135. Stroke therapy academic industry roundtable (Fisher M, Chair). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke* 1999;30:2752-2758.
136. Li F, Silva MD, Sotak CH, Fisher M. Temporal evolution of ischemic injury evaluated with diffusion, perfusion and T2-weighted MRI. *Neurology* 2000;54:689-696.
137. Li F, Carano RAD, Irie K, Sotak CH, Fisher M. Temporal evolution of average apparent diffusion coefficient threshold to define ischemic abnormalities in a rat permanent occlusion model. *J Stroke Cerebrovasc Disease* 2000;9:-7.
138. Li F, Liu KF, Silva MD, et al. Temporal evolution of reversibility of ischemic lesions on diffusion-weighted imaging. *Stroke* 2000;31:946-953.
139. Schabitz WR, Li F, Fisher M. The NMDA antagonist CNS-1102 protects cerebral gray and white matter from ischemia following temporary focal ischemia in the rat. *Stroke* 2000;31:1709-1714.
140. Li F, Liu KF, Silva, et al. Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. *Ann Neurol* 2000;48:236-244.
141. Fisher M, Schabitz WR. An overview of acute stroke therapy: past, present and future. *Arch Int Med* 2000;160: 3196-3206
142. Omae T, Mayzel-Oreg O, Li F, Sotak CH, Fisher M. Inapparent hemodynamic insufficiency exacerbates ischemic damage in a rat microembolic stroke model. *Stroke* 2000;31:2494-2499.
143. Tatlisumak T, Carano RA, Takano K, Meiler MR, Li F, Sotak CH, Arndts D, Pschorn U, Fisher M. Broad-spectrum cation channel inhibition by LOE 908 MS reduces infarct volume in vivo and postmortem in focal cerebral ischemia in the rat. *J Neurol Sci* 2000;178(2):107-113.
144. Combremont PC, Fisher M. Patients with acute stroke: recent developments in neuroimaging. *Curr Atherosclerosis Reports* 2000;2:136-143.
145. Moonis M, Fisher M. Imaging of Acute Stroke. *Cerebrovascular Disease* 2001;11: 143-150.
146. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies. *Stroke* 2001;32:1598-1606.
147. Liu KF, Li F, Tatlisumak T, Garcia JH, Sotak CH, Fisher M, Fenstermacher JD. Regional variations in the apparent diffusion coefficient and the intracellular distribution of water in rat brain during acute focal ischemia. *Stroke* 2001;32:1897-1905.
148. Li F, Silva M, Meng X, et al. Acute postischemic normalization of the apparent diffusion coefficient of water is not associated with reversal of astrocytic swelling and neuronal shrinkage. *AJNR* 2002;23:180-188.
149. Moonis M, Fisher M. Considering the role of heparin and low molecular heparins in acute ischemic stroke. *Stroke* 2002;33:1927-1933

150. Silva MD, Omae T, Helmer KG, Li F, Fisher M, Sotak CH. Separating changes in the intra- and extracellular water apparent diffusion coefficient following focal cerebral ischemia in the rat brain. *Magn Res Med* 2002;48:826-837.
151. Fisher M. Developing therapy for acute ischemic stroke. *Therapie* 2002;57:564-568.
152. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. *Ann Neurol* 2003;53:10-20.
153. Gerriets T, Li F, Silva MD, Meng X, Brevard M, Sotak CH, Fisher M. The macrosphere model: evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats. *J Neurosci Methods* 2003;122:201-211.
154. Shashoua VE, Adams DS, Boyer-Boiteau A, Cotrell-Bell A, Li F, Fisher M. Neuroprotective effects of a new synthetic peptide, CMX-9236, in in vitro and in vivo models of cerebral ischemia. *Brain Res* 2003;963:214-223.
155. Fisher M, Brott TG. Emerging therapies for acute ischemic stroke: new therapies on trial. *Stroke* 2003;34:359-361.
156. Recommendations for advancing development of acute stroke therapies. Fisher M for the Stroke Therapy Academic Industry Roundtable. *Stroke* 2003;34:1539-1546.
157. Gerriets T, Stolz E, Walberer M, Maps M, Bachman G, Fisher M. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion. *Stroke* 2003;34:2234-2239.
158. Shen Q, Meng X, Fisher M, Sotak CH, Duong TQ. Pixel by pixel spatiotemporal progression of focal ischemia derived using quantitative perfusion and diffusion imaging. *J Cereb Blood Flow Metab* 2003;23:1479-1488
159. Moonis M, Fisher M. Antiplatelet therapy for secondary prevention of acute ischemic stroke and transient ischemic attacks.: mechanisms, choices and possible emerging patterns of use. *Expert Rev Cardiovasc Ther.* 2003;1:611-615
160. Fisher M. Ongoing trials and future directions for acute ischemic stroke treatment. *Adv Neurol* 2003;92:401-408
161. Meng X, Fisher M, Shen Q, Sotak CH, Duong TQ. Characterizing the diffusion/perfusion mismatch in a rat stroke model of focal cerebral ischemia. *Ann Neurol* 2004;55:207-212
162. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. *Cerebrovasc Dis* 2004;17(suppl 1):1-6.
163. Fisher M, Davalos A. Emerging therapies for cerebrovascular disorders. *Stroke* 2004;35:367-369.
164. Moonis M, Fisher M. HMG CoA inhibitors (statins): use in stroke prevention and outcome after stroke. *Expert Rev Neurotherapeutics* 2004;4:241-247.
165. Shen Q, Fisher M, Sotak CH, Duong TQ. Effects of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke. *J Cereb Blood Flow Metab* 2004;24:280-290.
166. Shen Q, Ren H, Bouley J, Chen W, Fisher M, Duong TQ. Dynamic tracking of acute tissue fates using improved unsupervised ISODATA analysis of high-resolution quantitative perfusion and diffusion data. *J Cereb Blood Flow Metab* 2004;24:887-897.
167. Duong TQ, Fisher M. Applications of diffusion/perfusion MRI in experimental and clinical aspects of stroke. *Current Atherosclerosis Reports* 2004;6:257-263.
168. Kazemi M, Silva MD, Li F, Fisher M, Sotak CH. Investigation of techniques to quantify in vivo lesion volume based on comparison of water apparent diffusion coefficient (ADC) maps with histology in focal cerebral ischemia of rats. *Magn Res Med* 2004;22:653-659.
169. Gerriets T, Stolz E, Walberer M, Muller C, Kluge A, Bachman A, Fisher M, Kaps M, Bachman G. Noninvasive quantification of brain edema and space occupying effects in rat stroke models using magnetic resonance imaging. *Stroke* 2004;35:566-571

170. Gerreits T, Stolz E, Walberer M, et al. Middle cerebral artery occlusion during MR-imaging: of the hyperacute phase of stroke using a new in-bore occlusion model in rats. *Brain Res Protoc* 2004;12:137-143.
171. Mayzel-Oreg O, Omae T, Kazemi M, Li F, Fisher M, Cohen Y, Sotak CH. Microsphere-induced embolism stroke: An MRI study. *Magn Res Med* 2004; 51:1232-1238.
172. Gerreits T, Stolz E, Walberer M, Muller C, Rottger C, Klage A, Kaps M, Fisher M, Bachman G. Complications and pitfalls in rat stroke models for middle cerebral artery occlusion. *Stroke* 2004;35:2372-2377.
173. Ren H, Shen Q, Bardutzky J, Fisher M, Duong TQ. Partial-volume effect on ischemic tissue fate, delineation using quantitative perfusion and diffusion imaging on a rat stroke model. *Magn Res Med* 2004;52:1328-1335
174. Padma V, Fisher M, Moonis M. Antihypertensive medications for risk reduction of first and recurrent stroke. *Expert Rev Cardiovasc Ther* 2004;2:867-876.
175. Davalos A, Fisher M. Emerging therapies for cerebrovascular diseases. *Stroke* 2005;36:208-210.
176. Bardutzky J, Meng X, Bouley J, Ratan R, Duong T, Fisher M. Effects of iv dimethyl sulfoxide on ischemia evolution in a rat. *JCBFM* 2005;25:968-977.
177. Henning EC, Meng X, Fisher M, Sotak CH. Visualization of cortical spreading depression using manganese-enhanced magnetic resonance imaging. *Magn Res Med* 2005;53:851-857.
178. Moonis M, Kane K, Fisher M. HMG-COA reductase inhibitors improve acute ischemic stroke outcome. *Stroke* 2005;36:1298-1300
179. Padma V, Fisher M, Moonis M. Thrombolytic therapy for acute ischemic stroke: 3 hours and beyond. *Expert Review of Neurotherapeutics*. 2005;5:223-233.
180. Shen Q, Ren H, Fisher M, Duong TQ. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. *JCBFM* 2005;25:1265-1279.
181. Shen Q, Ren H, Fisher M, Duong TQ. Statistical prediction of tissue fate in acute in ischemic brain injury. *JCBFM* 2005;25:1336-1345.
182. Bardutzky J, Shen Q, Ren H, Duong TQ, Fisher M. Differences in ischemic lesion evolution in different rat strains using diffusion and perfusion imaging. *Stroke* 2005;36:2000-2005..
183. Bardutzky J, Shen Q, Bouley J, Sotak CH, Duong TQ, Fisher M. Perfusion and diffusion imaging in acute focal cerebral ischemia: temporal versus spatial resolution. *Brain Research* 2005;1043(1-2):155-162.
184. Stroke Therapy Academic Industry Roundtable. Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable (STAIR)-IV. *Stroke* 2005;36:1808-1813.
185. Fisher M. Developing and implementing future stroke therapies: The potential of telemedicine. *Ann Neurol* 2005;58:666-671.
186. Warach S, Kaufman D, Chiu D, et al. The effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo controlled trial. *Cerebrovasc Diseases* 2006;21:106-111.
187. Fisher M. Results of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Trial: Implications for the Neurologist. *Arch Neurol* 2006;63:20-24.
188. Fisher M. The ischemic penumbra: A new opportunity for neuroprotection. *Cerebrovasc Dis* 2006 (suppl 2) 64-70.
189. Henninger N, Sicard KM, Bouley J, Fisher M, Stagliano NE. The Proteasome inhibitor Velcade reduces infarction in rat models of focal cerebral ischemia. *Neurosci Lett* 2006;398:300-305.

190. Sicard KM, Henninger N, Fisher M, Duong TQ, Ferris C. Differential recovery of multimodal MRI and behavior after transient focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 2006;26:1451-1462.
191. Henninger N, Sicard KM, Schmidt K, Bardutzky J, Fisher M. Comparison of ischemic lesion evolution in embolic vs. mechanical middle cerebral artery occlusion in Sprague-Dawley rats using diffusion and perfusion imaging. *Stroke* 2006;37:1283-1287.
192. Fisher M, Cheung K, Howard G, Warach S. New pathways for evaluating potential acute stroke therapies. *Int Stroke Journal* 2006;1:52-58
193. Padma V, Fisher M, Moonis M. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. *Expert Rev Cardiovasc Ther* 2006;4:405-415.
194. Sicard KM, Henninger N, Fisher M, Duong TQ, Ferris CF. Long-term changes of fMRI-based brain function, behavioral status and histopathology after transient focal cerebral ischemia in rats. *Stroke* 2006;37:2593-2600.
195. Walberer M, Stolz E, Muller C, Friedrich C, Rottiger E, Blaus F, Kaps M, Fisher M, Bachmann G, Gerriets T. Experimental stroke ischemic lesion volume and oedema formation differs among rat strains. *Laboratory Animals* 2006;40(1):1-8
196. Fisher M, Henninger N. Translational research in stroke: taking advances in the pathophysiology and treatment of stroke from the experimental setting to clinical trials. *Curr Neurol Neurosci Reports* 2007;7:35-41.
197. Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative disorders *J Neuroimmunology* 2006;176:198-215.
198. Schabitz W, Fisher M. Perspectives on neuroprotective therapy. *Biochemical Society Transactions* 2006;34:1271-1276.
199. Bouley J, Fisher M, Henninger N. Comparison between coated vs. uncoated suture middle cerebral artery occlusion in rats as assessed by perfusion/diffusion weighted imaging. *Neurosci Lett* 2007;412:185-190.
200. Bardutzky J, Shen Q, Henninger N, Duong TQ, Schwab S, Fisher M. Characterizing tissue fate after transient focal ischemia of varying duration using quantitative diffusion and perfusion imaging. *Stroke* 2007;38:1336-1344.
201. Henninger N, Sicard KM, Fisher M. Spectacular shrinking deficit: Insights from multimodal magnetic resonance imaging after embolic middle cerebral artery occlusion in Sprague-Dawley rats. *JCBFM* 2007;27:1756-1763.
202. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. *Stroke* 2007;38:245-248
203. Lampi Y, Zivin JA, Fisher M, et al. Infrared laser therapy for ischemic stroke- a new treatment strategy: Results of the NeuroThera effectiveness and safety trial. *Stroke* 2007;38:1843-1849
204. Ali M, Bath PMW, Davis SM, Diener HC, Donnan GA, Fisher M, et al. The virtual international stroke trials archive (VISTA). *Stroke* 2007;38:1905-1910.
205. Henninger N, Bouley J, Nelligan J, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. *JCBFM* 2007;27:1632-1642
206. Savitz SI, Fisher M. The future of neuroprotection for acute stroke: In the aftermath of the SAINT trials. *Ann Neurol* 2007;61:396-402.
207. Savitz SI, Fisher M. Prophylactic neuroprotection. *Current Drug Targets* 2007;8:846-849
208. Henninger N, Fisher M. Stimulating circle of Willis nerve fibers preserves the diffusion-perfusion mismatch in experimental stroke. *Stroke* 2007;38:2779-2886
209. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis vs dichotomization of the mRS outcome scores in the NINDS and ECASS II trials. *Stroke* 2007;38:3205-3212.

210. Henninger N, Sicard KM, Li Z, Kulharni P, Dutzman S, Urbanek C, Schwab S, Fisher M. Differential recovery of behavioral status and brain function assessed with functional magnetic resonance imaging after mild traumatic brain injury in the rat. *Crit Care Med* 2007;35:2607-2614.
211. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. *Lancet* 2008;374:1612-1623
212. Fisher M, Folland E. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences. *Am J Therapeutics* 2008;2:137-149.
213. Langley B, D'Annibale, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, Ratan R. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity. *J Neurosci* 2008;28: 163-176
214. Fisher M, Bastan B. Treating acute ischemic stroke. *Current Opinion in Drug Discovery & Development* 2008;11(5):626-632.
215. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and late tPA in a rat embolic stroke model. *J Cereb Blood Flow Metab* 2009;29:119-129
216. Fisher M. Importance of early intervention in ischemic stroke and transient ischemic attacks. *Am J Manag Care* 2008;14:S204-211.
217. Savitz SI, Benatar M, Saver JS, Fisher M. Outcome analysis in clinical trial design for acute stroke: physicians attitudes and choices. *Cerebrovascular Diseases* 2008;26(2);156-162.
218. Phillips M, Benatar M, Fisher M, Savitz SI. Methodological variability of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. *Stroke* 2009;40:577-581
219. Macleod MR, Fisher M, O'Collins V, et al. Good laboratory practice: Preventing introduction of bias at the bench. *Stroke* 2009;40:e50-e52
220. Sicard KM, Fisher M. Emerging drugs for acute ischemic stroke. *Expert Opinion on Emerging Drugs* 2009;14 (1):1-10
221. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Laser Doppler predicts occlusion but not tPA-mediated reperfusion success after rat embolic stroke. *Exp Neurol* 2009;215:292-297.
222. Fisher M, Feuerstein GZ, Howells DW, et al. Update of the Stroke Therapy Academic Industry Roundtable preclinical recommendations. *Stroke* 2009;40:2244-2250.
223. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof T, Devlin T, Fisher M, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. *Stroke* 2009;40:1359-1364
224. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease *J Am Soc Nephrol.* 2009 Apr;20(4):705-11.
225. Morris JG, Duffis EJ, Fisher M. The cardiac workup of ischemic stroke: Can we improve our diagnostic yield? *Stroke* 2009;40:2893-2898
226. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M for the STAIR VI Consortium. Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Time Window Acute Stroke Therapy Trials. *Stroke* 2009;40:2594-2600
227. Fisher M. Does the combination of warfarin and aspirin have a place in secondary stroke prevention? *Stroke* 2009;40:1944-1945
228. Bratane B, Bastan B, Fisher M, Henninger N. Ischemic volume determination on diffusion weighted images vs. apparent diffusion coefficient maps. *Brain Research*;1279:182-188
229. Bratane B, Bouley J, Schneider A, Bastan B, Henninger N, Fisher M. Granulocyte colony stimulating factor delays mismatch evolution and reduces final infarct volume in permanent suture and embolic rat focal cerebral ischemia models. *Stroke* 2009;40:3102-3106
230. Henninger N, Chowdhury N, Fisher M, Moonis M. Use of telemedicine to increase thrombolysis and advance care in acute ischemic stroke. *Cerebrovascular Diseases* 2009;27(suppl 4), 9-14
231. Bratane B, Walvick RP, Corot C, Lancelot E, Fisher M. Characterization of Gadolinium based

DSC perfusion measurements in permanent and transient MCAO models with volumetric based validation by CASL JCBFM (in press)

232. Sicard KM, Fisher M. Animal models of focal brain ischemia. *Exp& Translational Stroke Medicine*. 2009;1:1-7

Editorials

1. Fisher M. Reversal of diffusion abnormalities after ischemic stroke: adding difficulty and complexity to the conundrum of acute stroke imaging. *Ann Neurol* 2003;52:695-696.
- 2.. Fisher M, Davalos A. The MATCH study results in the context of secondary stroke prevention. *Stroke* 2004; 35:2609.
- 3.Furlan A, Fisher M. Devices, drugs and the Food and Drug Administration: increasing implications for ischemic stroke. *Stroke* 2005;36:398-399.
- 4 Fisher M, Tatlisumak T. Use of animals models has not contributed to development of acute stroke therapies: contra. *Stroke* 2005;36: 2324-2325.
5. Henninger N, Fisher M. Normobaric hyperoxia-a promising approach to expand the time window for acute stroke treatment. *Cerebrovasc Dis* 2006;21:134-136.
- 6.Fisher M. Does neuroprotection with NXY-059 improve patient outcome after acute ischemic stroke? *Nat Clin Pract Cardiovasc Med* 2006 Jun;3(6):302-03
7. Fisher M. NXY-059 for acute ischemic stroke: The promise of neuroprotection is finally realized? *Stroke* 2006 37:60:
8. Fisher M. Is penumbral imaging useful for extending the treatment window for intravenous tissue plasminogen activator? *Ann Neurol* 2006;60:499-501.
9. Fisher M. Advances in stroke 2006: introduction. *Stroke* 2007;38:214-215
10. Fisher M. Advances in stroke 2007: introduction. *Stroke* 2007;39:250-251
11. Fisher M, Hachinski V. European Cooperative Acute Study III: Support for and questions about a truly emerging therapy. *Stroke* 2009;40:2262-2263.
12. Fisher M. Getting the word out on stroke guidelines. *Circulation* 2010 121:848-849

ABSTRACTS:

1. Fisher M, Fullerton AL, Duffy CP, Levine PH. Platelet Factor IV in Cerebrovascular Disease (abs). *Stroke* 1980; 11:129-130.
2. Fisher M, Levine PH, Fullerton AL, Duffy CP, Hoogasian JJ. Excessive Factor VIII Coagulant Activity in Transient Ischemic Attacks (abs). *Ann Neurol* 1980;8: 102.
3. Fisher M, Long RR, Drachman DA. Amyotrophy in Multiple Sclerosis (abs). *Ann Neurol* 1981;10: 95-96.
4. Fisher M, Sullivan J, Zivin JA, Russell J, Drachman DA. Status Epilepticus and Occult Epstein-Barr Virus Encephalopathy. *Neurology* 1982;32 (2): 77.
5. Fisher M, Weiner BH, Ockene IS, Forsberg A, Duffy CP, Levine PH. Platelet Activation and Mitral Valve Prolapse. *Neurology* 1982;32 (2): 197.
6. Fisher M, Wagle WA, Snyder TM, Zito JL, McQuillen JB. Spinal CT Scanning and

- Electromyography (EMG) in Lumbosacral Radiculopathy (LSR). *Neurology* 1983;33 (suppl 2):125.
7. Fisher M, Weiner B, Ockene IS, Hoogasian JJ, Ciccolini S, Levine PH. A New Approach to Antiplatelet Therapy. *Neurology* 1983;33 (suppl 2): 163-164.
 8. Fisher M, Zito JL, Siva A, DeGirolami U. Hemorrhagic infarction: A clinical and CT study. *Stroke* 1984;15: 192.
 9. Fisher M, Jackel R, Weiner B, Ockene IS, Johnson MH, Natale A, Levine PH. Platelet arachidonic acid in cerebrovascular and coronary artery disease. *Neurology* 1984;34 (suppl) 163.
 10. Zito JL, Fisher M, Siva A. Hemorrhagic infarction: Varying CT appearance. *Radiology* 1984;143: 167.
 11. Weiner BH, Ockene IS, Fisher M, Hoogasian JJ, Arsenault JR, Natale AM, Love DG, Levine PH. The effects of thromboxane synthetase inhibition in hyperlipidemia. *JACC* 1984;3: 498.
 12. Fisher M, Wyrzys L, Markley HG, Alfred HJ. Multiple mononeuropathies complicating brachial artery-antecubital vein shunting. *Neurology* 1985;35(suppl 1): 78.
 13. Fisher M, Weiner B, Ockene IS, Levine PH, Hoogasian J, Arsenault JR, Natale AM, Johnson MH, Vaudreuil CH. The effect of cod liver oil on platelets and prostaglandins. *Neurology* 1985;35 (suppl 1): 142.
 14. Zivin JA, Fisher M, DeGirolami U, Hemenway C. A method for the study of embolic stroke therapy. *Neurology* 1985;35 (suppl 1): 186.
 15. Fisher M, Przelomski M, Davidson RI, Marcus EM. Unruptured aneurysms presenting with focal ischemia: A follow-up study. *Neurology* 1985; 35 (suppl 1): 236.
 16. Zivin J, Fisher M, Degirolami V, Hemenway C. Tissue plasminogen activator therapy for embolic stroke. *Stroke* 1986;17: 133.
 17. Weiner B, Ockene IS, Levine PH, Fisher M, et al. Cod liver oil supplementation inhibits coronary atherosclerosis in swine. *JACC* 1986;7: 57.
 18. Phillips DA, Davis MA, Fisher M. Restoration of middle cerebral artery blood flow in rabbits following tissue plasminogen activator thrombolysis. *Circulation* 1986;74 (pt 2): 154.
 19. Fisher M, Phillips DA, Davis M, Smith TW. Tissue plasminogen activator in a large artery cerebral embolization model. *Stroke* 1987;18: 280.
 20. Fisher M, Levine PH, Weiner BH, et al. Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in MS. *Neurology* 1987;37(suppl 1): 296.
 21. Fisher M, Kase CS, Stelle B, Mills RM. Stroke after cardiac pacemaker in sick sinus syndrome. *Neurology* 1988;38(suppl 1): 216.

ABSTRACTS: (continued)

22. Fisher M, Recht L. Brain tumor presenting as pure motor stroke. *Neurology* 1988;38(suppl 1): 341.
23. Cohen RA, Fisher M. The efficacy of amantadine on self-reported and neurobehavioral correlates of fatigue in MS. *Neurology* 1988;38(suppl 1): 380.
24. Fisher M, Phillips DA, Smith TW, Davis MA, Pang RHL. Delayed treatment with a t-Pa analogue in an embolic stroke model. *Stroke* 1989;20: 25.
25. Kase CJ, O'Neal AM, Ordia JI, Girgis GN, Fisher M. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. *Neurology* 1989;39(suppl 1): 372.
26. Fisher M, Levine PH, Doyle EM, et al. The effects of a 21-aminosteroid on free radical production by human leukocytes. *Stroke* 1990; 21:24.
27. Fisher M, Levine PH, Doyle EM, Arpano MM, Bergeron DA, Hoogasian JJ. The effects of a novel steroid derivative, U74500A, on free radical production by monocytes from MS patients. *Neurology* 1990;40(suppl 1):
28. Kessler H, Cohen RA, Fisher M. Cognitive impairment as related to the measurement of disability in MS. *Neurology* 1990;40(suppl 1):141.
29. Fisher M, Hosley MA, Lingley JF. Congenital bifurcation of the superior sagittal sinus: an occult cause of venous thrombosis. *Stroke* 1991;22:136.
30. Rizzo MA, Ropper AH, Fisher M. Sacral myelitis. *Neurology* 1991;41(supl 1):426.
31. Minematsu K, Fisher M, Li L, Sotak CH, Davis MA. Diffusion weighted MRI rapidly detects focal brain abnormalities induced by suture occlusion of the MCA. *Neurology* 1991; 41: 1162.

32. Fisher M, Levine PH, Doyle EM, Arpano MM, Hoogasian JJ. Monocyte induced LDL-cholesterol oxidation is inhibited by a 21-aminosteroid, U74500A. *Neurology* 1991; 41:1163.
33. Minematsu K, Li L, Fisher M, Sotak CH, Davis MA. Diffusion weighted MRI displays reversible and irreversible injury in a temporary ischemia model. *Stroke* 1992; 23:145.
34. Fisher M, Nunnari J, White S, Majno G. Clentiazem inhibits early atherogenesis in a hypercholesterolemic rat atherosclerosis model. *Stroke* 1992; 23:162.
35. Minematsu K, Fisher M, Li L, Sotak CH. A non-competitive NMDA antagonist, CNS-1102, reduces ischemic injury *in vivo* and postmortem infarction area. *Neurology* 1992; 42(suppl 3):292.
36. Fisher M, Li L, Minematsu K, Sotak CH, Davis MA. Perfusion and diffusion-weighted MRI studies in a temporary rat stroke model. *Neurology* 1992; 42(suppl 3):362.
37. Fisher M, Plante GM, Doyle EM. A 21-aminosteroid, U74500A, inhibits myelin oxidation by inflammatory white blood cells. *Ann Neurol* 1992; 2:255.
38. Meadows ME, Fisher M, Minematsu K. Reduction of infarct size with a non-competitive NMDA antagonist, CNS-1102, given 1 hour after stroke onset. *Stroke* 1993; 24:161.
39. Minematsu K, Dardzinski BJ, Li L, Sotak CH, Fisher M. Diffusion studies of ischemic brain damage in an experimental temporary middle cerebral artery occlusion model in rats. *Stroke* 1993; 24:171.
40. Fisher M, Hasegawa Y, Baron B, Metcalf G. A novel competitive NMDA antagonist, MDL-10R,453, reduced infarct volume in experimental stroke. *Neurology* 1994; 44(suppl 2):A167.
41. Reith W, Hasegawa Y, Latour LL, Dardzinski BJ, Sotak CH, Fisher M. Multislice diffusion-weighted images for three-dimensional evolution of cerebral ischemia in a rat stroke model. *Neurology* 1994; 44(suppl 2):A181.
42. Anwer UE, Fisher M. Acute and atypical presentations of syringomyelia. *Neurology* 1994; 44(suppl 2):A228.
43. Hasegawa Y, Latour LL, Sotak CH, Fisher M, Formato JE. Spreading waves of reduced diffusion coefficient of water in the rat brain. *Neurology* 1994; 44(suppl 2):A341.
44. Hasegawa Y, Fisher M, Latour LL, Dardzinski BJ, Sotak CH. MRI diffusion mapping of reversible and irreversible ischemic injury in a temporary stroke model. *Stroke* 1994; 25:269.
45. Hasegawa Y, Latour LL, Dardzinski BJ, Sotak CH, Fisher M. MRI assessment of temperature dependent changes of the apparent diffusion coefficient of water in normal and ischemic rat brain. *Stroke* 1994; 25:269.
46. Takano K, Formato JE, Tatlisumak T, et al. Effects of the glycine antagonist, ZD9379, on experimental focal brain ischemia in rats. *Stroke* 1996; 27:188
47. Takano K, Latour LL, Formato JE, et al. Spreading depression contributes to the evolution of focal brain ischemia evaluated by diffusion mapping. *Stroke* 1996; 27:184.

ABSTRACTS (continued)

48. Tatlisumak T, Takano K, Carano RAD, et al. Basic fibroblast growth factor reduces infarct size *in vivo* and *post mortem* in permanent experimental focal ischemia. *Stroke* 1996; 27:192.
49. Meden P, Tatlisumak T, Takano K, et al. Thrombolysis with recombinant desmodus saliva plasminogen activator in a rat embolic stroke model. *Cerebrovasc Dis* 1996; 6:190.
50. Takano K, Carano RAD, Tatlisumak, et al. The efficacy of intra-arterial and intravenous Pro-Urokinase in an embolic stroke model. *Neurology* 1997;48:A409.
51. Li F, Onal Z, Tatlisumak T, et al. Combined treatment with citocoline and MK-801 reduces infarct volume in temporary focal ischemia. *Neurology* 1997;48:A409.
52. Li F, Carano RAD, Meng X, Irie K, Sotak CH, Fisher M. The ischemic lesion volume determined by tracing the hyperintense border on diffusion-weighted imaging: Correlation with the ADC-derived lesion volume and the final infarct volume in experimental rat stroke. *Radiology* 1997;205 (p):36.
53. Li F, Carano R, Irie K, Sotak C, Fisher M. The time course of the average apparent diffusion coefficient threshold to predict ischemic lesion size in a rat permanent occlusion mode. *Stroke* 1998;29: 278.
54. Li F, Tatlisumak T, Han S, Irie K, Liu KF, Garcia J, Sotak C, Fisher M. Apparent diffusion coefficient maps and histological analysis of varying time periods of temporary focal brain ischemia in the rat. *Stroke* 1998;29:329.

55. Tatlisumak T, Takano K, Meiler M, Fisher M. Glycine site antagonism reduces number of spreading depressions and infarct size in rats. *Stroke* 1998;29:331.
56. Li F, Silva MD, Sotak CH, Fisher M. Temporal evolution of secondary ischemic injury in transient focal brain ischemia. Evaluated with diffusion-perfusion and T2-weighted imaging. *Stroke* 1999;30:276.
57. Li F, Silva MD, Liu KF, et al. High temporal resolution monitoring of secondary apparent diffusion Coefficient decline following mild focal ischemia in rat. *Stroke* 2000;31:340.
58. Li F, Liu KF, Silva MD, et al. Temporal evolution of ischemic lesions on diffusion-weighted imaging: correlation with histopathology. *Stroke* 2000;31:340.
59. Omae T, Silva MD, Mayzel-Org O, et al. Temporal evolution of diffusion/perfusion mismatch in a rat stroke model. *Stroke* 2001;32: 351.
60. Li F, Silva MD, Meng X, et al. Prediction of secondary ischemic lesions with diffusion-weighted imaging after transient middle cerebral artery occlusion in rats. *Stroke* 2001;32: 352.
61. Meng X, Li F, Silva MD, Sotak CH, Fisher M. Growth patterns of ischemic lesions with different initial volume in a permanent middle cerebral artery occlusion model. *Stroke* 2001;32: 356.

BOOK CHAPTERS:

1. Fisher M. Ischemic Cerebrovascular Disease. Editors: Rippe JM, Irwin RS, Alpert JS, Dalen JE in *Intensive Care Medicine*, Boston, Little Brown, 1985.
2. Berarducci AL, Fisher M, Davidson RI. Intracranial Hemorrhage. Editors: Rippe JM, Irwin RS, Alpert JS, Dalen JE in *Intensive Care Medicine*, Boston, Little Brown, 1985.
3. Fisher M, Levine PH, Weiner BH, Omega-3 Fatty Acids and Atherosclerosis. Editors: Hennirici M, Sitzer G, Weger H-D in *Carotid Artery Plaques*, Karger, Basel, 1988, pp. 92-100.
4. Fisher M, Phillips DA, Smith TW, Davis MA, Pang RHL. Early and Delayed Thrombolytic Therapy in a Rabbit Cerebral Embolization Model Using a t-PA Analogue. Eds: Ginsburg, MD, Dietrich WD in *Proceedings of the 16th Princeton Conference on Cerebrovascular Diseases*, Raven Press. New York, 1989, pp. 29-32.
5. Fisher M, Levine PH, Weiner BK, Johnson MH, Hoogasian, JJ. Dietary Omega-3 Fatty Acid Supplementation Prolongs Platelet Survival in an Atherosclerotic Hyperlipidemic Population. Editors: Ginsburg M, Dietrich WD in *Proceedings of the 16th Conference on Cerebrovascular Disease*, Raven Press. New York, 1989, pp. 237-241.
6. Fisher M. Cellular Basis of Atherosclerosis. Editors: Norris JW, Hachinski VC in *Prevention of Stroke*, Springer Verlag 1991, pp. 19-36.
7. Kase CS, Fisher M, Babikian VL, Mohr JP. Cerebrovascular Disease. Editor: Rosenberg R in *Contemporary Neurology*, Raven Press 1991, pp. 97-156.
8. Fisher M. Cellular Aspects of Atherosclerosis and Approaches to Intervention: A Mechanism to Reduce Stroke and Vascular Dementia Risk. Editors: Hartmann A, Kuschinsky W, Hoyer S in *Cerebral Ischemia and Dementia*, Springer Verlag, Heidelberg, 1991, pp. 69-76.
9. Young SM, Fisher M, Davidson RI. Cerebrovascular Disease. Editors: Rippe JM, Irwin RS, Alpert JS, Fink MP in *Intensive Care Medicine: 2nd Edition*, Little Brown, Boston, 1991, pp. 1570-1581.

BOOK CHAPTERS (CONT'D.)

10. DeGraba TJ, Fisher M, Yatsu FM. Atherogenesis and strokes. Editors: Barnett HJM, Mohr JP, Stein BM, Yatsu FM in *Stroke: 2nd Edition*, Churchill Livingstone 1992, pp. 29-48.
11. Fisher M. Risk factors and potential interventions for vascular dementia. Editors: Culebras A, Mataias Guiu J, Roman G in *New Concepts in Vascular Dementia*, Prous Science, 1993, pp. 9-16.
12. Fisher M, Minematsu K. Cerebrovascular disorders. Editors: Hurst JW, Alpert JS in *Diagnostic Atlas*

- of the Heart*, Raven Press, New York, 1994, pp. 481-502 .
13. Fisher M. Diffusion-perfusion MRI and magnetic resonance spectroscopy. Editors: Greenberg JO in *Neuroimaging*, McGraw-Hill, New York, 1994, pp. 599-606.
 14. Fisher M. An overview of cytoprotective therapy for acute ischemic stroke. Editors: Moskowitz MA, Caplan LP. *Proceedings of the 19th Princeton Conference on Cerebrovascular Diseases*. Butterworth-Heinemann, Boston, 1995, pp. 391-403.
 15. Fisher M. Atherosclerosis. Editor: Caplan LR in *Brain Ischaemia*, Springer-Verlag, London 1995, pp. 135-150.
 16. Fisher M, Takano K. The penumbra, therapeutic time window and acute ischaemic stroke. Editors: Hachinski V in *Cerebrovascular Disease*, Bailliere-Tindall, London, 1995, pp. 279-296.
 17. Fisher M. Application of diffusion-weighted magnetic resonance imaging for stroke diagnosis and treatment. Editors: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ in *Thrombolytic Therapy in Acute Ischemic Stroke, III*, Springer, Tokyo, 1995, pp. 115-123.
 18. Fisher M, Weaver JP. Cerebrovascular disease. Editors: Rippe JM, Irwin RS, Fink MP, Cerra FB in *Intensive Care Medicine*, Little Brown, Boston, 1996, pp. 2010-2019.
 19. Weaver JP, Hanley D, Danchev D, Fisher M. Subarachnoid hemorrhage. Editors: Rippe JM, Irwin RS, Fink MP, Cerra FB in *Intensive Care Medicine*, Little Brown, Boston, 1996, pp. 2051-2060.
 20. Fisher M, Warach S. New Magnetic Resonance Imaging Techniques for Stroke Diagnosis and Treatment. Editor: Hsu CY in *Ischemic Stroke: From Basic Mechanisms to New Drug Development*, Karger, Basel, Switzerland, 1998, pp. 139-150.
 21. Silver B, Fisher M. Trends in Protecting Ischemic Brain. Editor: Bogousslavsky J in *Acute Stroke Treatment*, Martin Dunitz Ltd, London, 1997, pp. 149-162.
 22. Sacco RL, Fisher M. Prophylactic Neuroprotection for Pretreatment of Brain Infarction. Editor: Bogousslavsky J in *Acute Stroke Treatment*, Martin Dunitz Ltd, London, 1997, pp. 271-284.
 23. Rajmani K, Fisher M. Atherosclerosis: Pathogenesis and Pathophysiology. Editor: Ginsberg MD, Bogousslavsky J in *Cerebrovascular Disease*. Blackwell Science, Malden, 1998, pp. 308-318.
 24. Fisher M. Anti-ischemic Stroke Therapy. Editors Ginsberg MD, Bogousslavsky J. in *Cerebrovascular Disease*. Blackwell Science, Malden, 1998, pp. 1876-1886.
 25. Schaebitz WR, Combremont P, Fisher M. Diagnostic Testing in Neurology, editor, Evans RW, Saunders, Philadelphia, 1999, pp 57-78.
 26. Schaebitz WR, Fisher M. Diffusion-perfusion MRI and magnetic resonance spectroscopy in cerebrovascular disease. Editor Greenberg JO, *Neuroimaging*, McGraw-Hill, New York, 1999, pp 625-634.
 27. Moonis M, Fisher M. Advances in Imaging in Ischemic Stroke. Editor Pinsky MR. In *Cerebral Blood Flow.: Mechanisms of Ischemia, Diagnosis and Therapy*. Springer, Berlin, 2001. pp 191-200.
 28. Fisher M, Orberk E, Ramzan M. Neurovascular Disorders, editor Evans RW, In *Saunders Manual of Neurologic Practice*, W. B. Saunders, Philadelphia, 2003, pp148-175.
 29. Fisher M. Ongoing trials and future directions for acute ischemic stroke treatment. Editors Barnett HJM, Bogousslavsky J, Meldrum H. in *Advances in Neurology Volume 92: Ischemic Stroke*, Lippincott, Williams and Wilkins, Philadelphia, 2003, pp401-408.
 30. Fisher M. Imaging as a surrogate marker in clinical trials. In *Imaging Cerebrovascular Disease*, Editors Babikian VL, Wechsler LR, Higashida RT, Butterworth Heinemann, Boston, 2003, pp371-382.
 31. Moonis M, Fisher M. Combination therapies, restorative therapies and future directions. In *Acute Stroke Treatment*, Editor Bogousslavsky J, Martin Dunitz, London, 2003, pp309-316.
 32. Fisher M. Using diffusion-perfusion MRI in animal models for drug development. In *Magnetic Resonance Imaging in Stroke*, Editors Davis S, Fisher M, Warach S, Cambridge University Press, 2003, pp113-120.
 33. Fisher M. Identification and treatment of stroke risk factors in *Approaches to Cerebrovascular Disease*, Prous Science, 2006, 1-12.
 34. Fisher M, Lo EH, Lev M. Imaging in experimental neurology in *Handbook of Experimental Neurology*, Editors, Tatlisumak T and Fisher M, Cambridge University Press, 2006, 132-146.
 35. Fisher M, Kumar R. Implications of stroke pathophysiology and the ischemic penumbra in *Stroke Practical Guide for Clinicians*, Editor Bornstein NM, Karger, 2009, 24-36.

BOOKS:

1. Fisher M (editor). *Clinical Atlas of Cerebrovascular Disease*. Gower-Mosby, New York 1993.
2. Fisher M, Bogousslavsky J (editors). *Current Review of Cerebrovascular Disease*. Current Science, Philadelphia 1993.
3. Fisher M (editor). *Stroke Therapy*. Butterworth-Heinemann.
4. Fisher M, Bogousslavsky J (editors). *Current Review of Cerebrovascular Disease, II*. Current Science, Philadelphia 1995.
5. Bogousslavsky J, Fisher M (editors). *Textbook of Neurology*. Butterworth-Heinemann, 1998.
6. Fisher M, Bogousslavsky J (editors). *Current Review of Cerebrovascular Disease - 3*. Current Science, 1998.
7. Fieschi C, Fisher M (editors). *Stroke Prevention*, Martin Dunitz, 1999.
8. Fisher M, Bogousslavsky J (editors). *Current Review of Cerebrovascular Disease-4*, Current Science, Philadelphia, 2000.
9. Fisher M (editor). *Stroke Therapy*, 2nd edition, Butterworth-Heinemann, Boston, 2001
10. Davis S, Fisher M, Warach S (editors). *Magnetic Resonance Imaging in Stroke*. Cambridge University Press, Cambridge, 2003.
11. Tatlisumak T, Fisher M (editors). *Handbook of Experimental Neurology*, Cambridge University Press, Cambridge, 2006
12. Fisher M (editor), *Approaches to Cerebrovascular Disease (monograph)*, Prous Sciences, Barcelona, 2006
13. Fisher M (editor) *Handbook of Clinical Neurology Volume 92, Stroke Part I: Basic and epidemiological aspects*, Elsevier, Edinburgh, 2009
14. Fisher M (editor) *Handbook of Clinical Neurology Volume 93, Stroke Part II: Clinical manifestations and pathogenesis*, Elsevier, Edinburgh, 2009
15. Fisher M (editor) *Handbook of Clinical Neurology Volume 94, Stroke Part III: Investigation and management*, Elsevier, Edinburgh, 2009

PHARMACEUTICAL GRANTS: Principal Investigator

1. Upjohn Company, January 1981.
2. Dupont Pharmaceuticals, 1986.
3. Bayer Pharmaceuticals and Bessalar Associates, 1986.
4. Miles Pharmaceuticals, 1989.
5. Miles Pharmaceuticals, 1989.
6. Marion Merrill Dow, 1990.
7. The Upjohn Company, 1990.
8. Cambridge NeuroScience, 1991.
9. Otsuka Pharmaceuticals, 1991.
10. Miles Pharmaceuticals, 1992.
11. Marion Merrill Dow, 1992.
12. Parke Davis, 1992.

13. Cambridge NeuroScience, 1993.
14. Parke Davis, 1993.
15. Upjohn, 1993.
16. Janssen Pharmaceuticals, 1993.
17. Interneuron, 1994.
18. Neurogen, 1994.
19. Zeneca, 1994.
20. Scios-Nova, 1994.
21. Zeneca, 1995.
22. Schering, 1995.
23. Abbott, 1995.
24. Gensia, 1995.
25. Bristol-Meyers, 1996.
26. Abbott Laboratories, 1996.
27. Boehringer-Ingelheim, 1997.
28. Glaxo-Wellcome, 1997.
29. Schering, 1997.
30. Interneuron, 1998.
31. Pfizer, 1999.
32. Abbott, 1999.
33. Elan 2000
34. Pharms 2001
35. Bristol-Myers Squibb 2001
36. Boehringer-Ingelheim 2002
37. Suntory Pharmaceuticals 2002
38. APT Therapeutics 2003
39. Millenium Pharmaceuticals 2005
40. Xigen Pharmaceuticals 2005
41. Biogenidec 2005
42. Amkor 2006
43. Brainsgate 2006
44. Fibrogen 2006
45. Servier 2006
46. **Wyeth 2008**
47. **Sygnis 2008**
48. **Guebert 2009**

NIH SPONSORED TRIALS

1. International Unruptured Aneurysm Study, 1992 to 1998. (Local Principal Investigator)
2. NASCET, 1994 to 1998. (Local co-Principal Investigator)

PHARMACEUTICAL INDUSTRY COLLABORATIONS

1. Cambridge NeuroScience, 1992-1994. Steering committee Phase I and II: Clinical trials of CNS-1102 in acute stroke.
2. Lorex Pharmaceuticals, 1993-1995. Steering and imaging committees: North American Eliprodil acute stroke trial

3. Bristol Myers Squibb, 1998-2001 Principal Investigator: A Maxi-Potassium Channel Antagonist.
4. Eli-Lilly, Centacor, 1998 -1999 Steering Committee, ReoPro Stroke Study.
5. GlaxoWellcome 1998-1999 Member Steering Committee, GAIN MRI substudy

6. PAION Advisory committee DIAS study
7. PhototheraThera Scientific Advisory Board
8. Daiichi Asubio steering committee phase IIB stroke trial
9. Axaron scientific advisory board
10. Servier, steering committee, PERFORM trial
11. Photothera, steering committee, NEST trial
12. Coaxia steering committee, SENTIS trial

ENDOWED RESEARCH FUNDS

1. Francis A. and Jacquelyn H. Harrington Neurological Research Fund, 1987-2002.
2. Neurology-Stroke Research Fund-UMASS/Memorial Healthcare

RESEARCH FELLOWS TRAINED

Kazuo Minematsu

Yashiro Hasegawa

Kentaro Takano

Turgut Tatlisumak

Wolfgang Reith

Fuhai Li

Katsumie Irie

Tsuyoshi Omae

Zulkuf Onal

Wolf Schaebitz

Pierre Combremont

Erdem Orberg

Xiangjun Meng

Juergen Bardutzky

Nils Henninger

Kenneth Sicard (MD-PhD student)

Birgul Bastan

PhD STUDENTS (WITH WPI)

Lawrence Latour

Bernard Dardzinski

Richard Carano

Matthew Silva

NATIONAL GRANT REVIEW AND OTHER COMMITTEES

American Heart Association, Brain Study Section, 1996-2000.

Vice-Chairman, 1999.

Buegher Grant Committee, AHA, 2001, 2005

National Stroke Association, Fellowship Committee, 1996-present.

Chairman, 2000-present.

Ad hoc reviewer, NINDS, NIA.

Bristol-Myers Squibb, National Neuroscience Advisory Board, 2000

National Stroke Association, Board of Directors, 2003-present

American Stroke Association Annual Meeting Program Committee, 2004-present

International Stroke Society Steering Committee, 2004-present

Johnson&Johnson, Stroke Advisory Board, 2004-present

Marc Fisher, MD

September 2, 2008